| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The primary reported target for N-Methyl-L-threonine is the herpes simplex virus (HSV), where it has been shown to inhibit HSV replication. The compound's mechanism of action involves preventing viral attachment to the host cell and blocking viral penetration into host cells. Additionally, as an amino acid derivative, it may play a role in neurotransmitter synthesis, suggesting potential targets in neurological disorders. However, specific protein or enzyme targets have not been definitively identified, and its activity is primarily associated with its antiviral properties and its role as a building block for bioconjugation.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
N-Methyl-L-threonine has demonstrated in vitro activity against herpes simplex virus (HSV) by inhibiting viral replication. The compound prevents HSV from attaching to and penetrating host cells, thereby blocking the initial stages of infection. This in vitro antiviral activity suggests its potential as a lead compound for the development of new antiviral therapies. In addition to its antiviral effects, amino acid derivatives like N-Methyl-L-threonine are known to influence the secretion of anabolic hormones and fuel supply during exercise, although these effects are more associated with their use as ergogenic supplements. |
| ln Vivo |
In vivo activity of N-Methyl-L-threonine has been reported in the context of clinical use for the prevention and treatment of herpes simplex virus (HSV) infection. This suggests that the compound or its formulations have been evaluated in vivo and have shown efficacy against HSV. However, detailed in vivo animal study data is not readily available. The compound's ability to inhibit HSV replication in vivo supports its potential therapeutic application. Further research would be needed to fully characterize its in vivo pharmacological profile, including its efficacy, safety, and dosing regimen in animal models of HSV infection.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N-Methyl-L-threonine would focus on its antiviral mechanism. A typical protocol to assess its binding to HSV could involve a viral attachment assay. In this assay, host cells are pre-incubated with various concentrations of the test compound at 4°C to allow binding but prevent internalization. After washing, the cells are infected with HSV, and the amount of bound virus is quantified using PCR or immunofluorescence. This approach directly measures the compound's ability to block viral attachment to the host cell surface, which is one of its proposed mechanisms of action.
|
| Cell Assay |
In vitro cell-based assays for N-Methyl-L-threonine would typically involve testing its antiviral activity against HSV in cultured cells. A common protocol is the plaque reduction assay. In this assay, Vero cells or other susceptible cell lines are grown in multi-well plates and infected with HSV in the presence of varying concentrations of the test compound. After incubation, the cells are overlaid with a medium containing agarose to prevent viral spread, and plaques are stained and counted. The concentration of compound required to reduce the number of plaques by 50% (EC50) is determined, providing a measure of its antiviral potency.
|
| Animal Protocol |
In vivo animal experiments for N-Methyl-L-threonine would likely involve mouse models of HSV infection. A typical protocol could involve infecting mice with HSV via the intraperitoneal or intranasal route, followed by treatment with the compound administered orally or intraperitoneally. The animals would be monitored for survival, clinical signs of infection, and viral titers in target tissues such as the brain or skin. This model would allow for the evaluation of the compound's efficacy in a living system and the determination of its therapeutic window.
|
| ADME/Pharmacokinetics |
N-Methyl-L-threonine has a molecular weight of 133.15 g/mol (free base) and 169.65 g/mol as the hydrochloride salt. Its pharmacokinetic properties have not been fully characterized in the literature. As an amino acid derivative, it is likely to be absorbed through peptide transporters and distributed to various tissues. The compound may be metabolized through pathways similar to other amino acids. Its hydrochloride salt form enhances its aqueous solubility, which is favorable for formulation. However, detailed ADME data, including half-life, bioavailability, and clearance, are not available. Further pharmacokinetic studies would be required to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for N-Methyl-L-threonine is limited. As a research chemical, it is not intended for human use, and comprehensive toxicity studies have not been reported. The compound is generally considered safe for laboratory handling with standard precautions. Its hydrochloride salt form may cause irritation upon contact. No specific information regarding acute toxicity, genotoxicity, or reproductive toxicity is available. Given its structural similarity to the natural amino acid threonine, it may have a low toxicity profile, but this has not been formally established.
|
| References | |
| Additional Infomation |
N-Methyl-L-threonine is a threonine derivative with potential applications in antiviral therapy and drug delivery. It has been shown to inhibit HSV replication by blocking viral attachment and penetration. The compound is also used in bioconjugation to improve drug targeting. It is commercially available for research purposes only and is not approved for clinical use. As an amino acid derivative, it may also be used as an ergogenic supplement to influence hormone secretion and exercise performance. Further research is needed to fully elucidate its mechanism of action and therapeutic potential.
|
| Molecular Formula |
C5H11NO3
|
|---|---|
| Molecular Weight |
133.15
|
| Exact Mass |
133.074
|
| CAS # |
2812-28-4
|
| PubChem CID |
7010355
|
| Appearance |
White to off-white solid powder
|
| LogP |
-3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O([H])[C@]([H])(C([H])([H])[H])[C@@]([H])(C(=O)O[H])N([H])C([H])([H])[H]
|
| InChi Key |
CCAIIPMIAFGKSI-DMTCNVIQSA-N
|
| InChi Code |
InChI=1S/C5H11NO3/c1-3(7)4(6-2)5(8)9/h3-4,6-7H,1-2H3,(H,8,9)/t3-,4+/m1/s1
|
| Chemical Name |
(2S,3R)-3-hydroxy-2-(methylamino)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 50 mg/mL (375.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5103 mL | 37.5516 mL | 75.1033 mL | |
| 5 mM | 1.5021 mL | 7.5103 mL | 15.0207 mL | |
| 10 mM | 0.7510 mL | 3.7552 mL | 7.5103 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
